Sam Brusco, Associate Editor02.04.22
Ambu received U.S. Food and Drug Administration (FDA) 510(k) clearance for its aScope Gastro single-use gastroscope and aBox 2 display unit. aScope Gastro is Ambu’s first sterile, single-use gastroscope and features updated imaging and design features.
The new gastroscope could be an attractive choice for gastroscopies across endoscopy units, operating rooms, intensive care units, emergency rooms, and ambulatory surgical centers. The company aims to reduce waiting lists and surmount staff shortages, which have occurred more frequently since the COVID-19 pandemic’s beginning.
A sterile product also addresses cross-contamination risks, especially for vulnerable patients.
“In the OR setting, having a single-use scope that is immediately available with a small footprint, which requires much less up-front capital outlay than a reusable setup, will be valuable to many hospitals across the country,” Reginald Bell, M.D., F.A.C.S, Institute of Esophageal and Reflux Surgery, told the press.
aScope Gastro is the next step in Ambu’s move into the gastrointestinal (GI) segment, following a recent aScope Duodeno 1.5 launch. The company plans to follow up with aScope Duodeno 2.0, a colonoscope, and a cholangioscope.
“Gastroscopy is not only one of the largest segments in endoscopy, but also has all the conditions to benefit from single-use endoscopy. There is a clear need for more convenience, flexibility, and infection control, which are all addressed with the introduction of our aScope Gastro,” said Juan Jose Gonzalez, CEO of Ambu. “The technology in our aScope Gastro and aBox 2 will set a new benchmark in terms of image quality and functionality and will power all of our next-generation launches. Our expansion within GI will extend Ambu’s position as the world’s most innovative single-use endoscopy player.”
The new gastroscope could be an attractive choice for gastroscopies across endoscopy units, operating rooms, intensive care units, emergency rooms, and ambulatory surgical centers. The company aims to reduce waiting lists and surmount staff shortages, which have occurred more frequently since the COVID-19 pandemic’s beginning.
A sterile product also addresses cross-contamination risks, especially for vulnerable patients.
“In the OR setting, having a single-use scope that is immediately available with a small footprint, which requires much less up-front capital outlay than a reusable setup, will be valuable to many hospitals across the country,” Reginald Bell, M.D., F.A.C.S, Institute of Esophageal and Reflux Surgery, told the press.
aScope Gastro is the next step in Ambu’s move into the gastrointestinal (GI) segment, following a recent aScope Duodeno 1.5 launch. The company plans to follow up with aScope Duodeno 2.0, a colonoscope, and a cholangioscope.
“Gastroscopy is not only one of the largest segments in endoscopy, but also has all the conditions to benefit from single-use endoscopy. There is a clear need for more convenience, flexibility, and infection control, which are all addressed with the introduction of our aScope Gastro,” said Juan Jose Gonzalez, CEO of Ambu. “The technology in our aScope Gastro and aBox 2 will set a new benchmark in terms of image quality and functionality and will power all of our next-generation launches. Our expansion within GI will extend Ambu’s position as the world’s most innovative single-use endoscopy player.”